Clinical Trials Logo

Clinical Trial Summary

This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the toxicity of MSC, given to healthy adult males as a single oral dose.

SECONDARY OBJECTIVES:

I. To characterize the pharmacokinetics of single oral doses of MSC in healthy adult male volunteers.

II. To evaluate the baseline selenium content of toenail clippings in healthy adult males.

OUTLINE: This is a multicenter, randomized, placebo controlled, double blind, dose escalation study. Participants are randomized to 1 of 2 arms.

Arm I: Participants receive oral placebo on day 1.

Arm II: Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.

Participants undergo blood, urine, and toenail clipping collection for pharmacokinetic and correlative studies. Samples are analyzed for plasma protein levels of selenium for proteomic and gene expression, molecular fingerprinting by mass spectrometry, and RNA by gene array analysis.

After completion of study treatment, participants are followed at 7-14 days and at 30 days. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00489372
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 1
Start date July 2007
Completion date July 2009

See also
  Status Clinical Trial Phase
Completed NCT01950403 - Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers Phase 1
Terminated NCT01561989 - Cholecalciferol and Flu Vaccine in Treating Healthy Participants N/A
Terminated NCT01336387 - Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers Phase 1
Completed NCT01140646 - Evaluation of SAMe for Hot Flashes Phase 2
Completed NCT00892515 - Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer N/A
Completed NCT00450957 - Lycopene in Healthy Male Participants Phase 1
Completed NCT00365209 - Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) Phase 2
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Completed NCT02100254 - Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities N/A
Completed NCT02129517 - Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials N/A
Terminated NCT01755208 - Light-Scattering Spectroscopy for Detection of Breast Cancer N/A
Completed NCT00499460 - Effects of Garlic Supplements on Opioids in Healthy Volunteers Phase 4
Completed NCT00392652 - Diindolylmethane in Healthy Volunteers Phase 1
Completed NCT01077453 - Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer Phase 1
Completed NCT00478309 - Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants N/A
Completed NCT01370889 - Resveratrol in Postmenopausal Women With High Body Mass Index Phase 1
Completed NCT00896207 - Studying Different Formulations of SR13668 in Healthy Volunteers Phase 1
Completed NCT00679094 - Bowman-Birk Inhibitor Concentrate in Healthy Men Phase 1
Terminated NCT02154984 - Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants N/A
Completed NCT00513916 - Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women Phase 3